Evidence map›Paper›PMID 32152098›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2020

The Tol-Pal system is required for peptidoglycan-cleaving enzymes to complete bacterial cell division.

Anastasiya A Yakhnina, Thomas G Bernhardt

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
13.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 129 citations in OpenAlex.

  1. Article
  2. Article
  3. Multiple TonB-dependent transport systems inInfection and immunity · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. A nonenzymatic effector disruptsProceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Anastasiya A YakhninaDepartment of Microbiology, Harvard Medical School, Boston, MA 02115.
Thomas G BernhardtDepartment of Microbiology, Harvard Medical School, Boston, MA 02115; thomas_bernhardt@hms.harvard.edu.
Harvard University · USHoward Hughes Medical Institute · US

Funding

Peptidoglycan Biogenesis in Escherichia ColiR01AI083365 · NIAID · HARVARD MEDICAL SCHOOL · PI Thomas G Bernhardt · 2010 to 2026
$8.3M
Targeting cell separation systems of gram-negative bacteria.R33AI111713 · NIAID · HARVARD MEDICAL SCHOOL · PI BERNHARDT, THOMAS G · 2016 to 2018
$1.5M
Targeting cell separation systems of gram-negative bacteria.R21AI111713 · NIAID · HARVARD MEDICAL SCHOOL · PI BERNHARDT, THOMAS G · 2014 to 2015
$462k
Howard Hughes Medical InstituteNIAID NIH HHS R01 AI083365NIAID NIH HHS R21 AI111713NIAID NIH HHS R33 AI111713
6 · The paper itself

Abstract

Tol-Pal is a multiprotein system present in the envelope of Gram-negative bacteria. Inactivation of this widely conserved machinery compromises the outer membrane (OM) layer of these organisms, resulting in hypersensitivity to many antibiotics. Mutants in the

Indexed as

Cell DivisionBacterial Outer Membrane ProteinsCell MembraneCell WallEscherichia coliEscherichia coli ProteinsLipoproteinsPeptidoglycanProtein BindingBacterial Outer Membrane ProteinsEscherichia coli ProteinsLipoproteinsPeptidoglycancell wallcolicindivisomepeptidoglycan

Identifiers

PMID32152098
PMCPMC7104345
OpenAlexW3010145555

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.